ClinicalTrials.gg
RecruitingNCT06786949BC-NSW-02/2023Updated Jan 22, 2025

Night-shift Work and Breast Cancer

An observational study in Breast Cancer Risk Factors, sponsored by IRCCS Azienda Ospedaliero-Universitaria di Bologna. Recruiting at 2 sites in Italy. Open to female participants aged 20 Years to 70 Years. Per ClinicalTrials.gov, last updated 2025-01-22.

Sponsored by IRCCS Azienda Ospedaliero-Universitaria di Bologna · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Jun 2025, 1 year 4 months ago, but the record still lists the study as recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
6,000
Ages
20 Years to 70 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 13 studies in Breast Neoplasms by IRCCS Azienda Ospedaliero-Universitaria di Bologna — 7 open to participants now, 9 under way, none of them phase 3. Breast Neoplasms · IRCCS Azienda Ospedaliero-Universitaria di Bologna.

Started
2025
with 1 other
Observational
8 of 13
5 open now
Registered
10th of 13
by date

Among the 13 studies in Breast Neoplasms by IRCCS Azienda Ospedaliero-Universitaria di Bologna, this one is one of 2 that started in 2025, is one of 8 observational ones, and was the 10th registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

7 of the 13 studies in Breast Neoplasms by IRCCS Azienda Ospedaliero-Universitaria di Bologna are open now, in 1 country. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 7 open studies →

Where they have run

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 20 Years to 70 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Breast Neoplasms by IRCCS Azienda Ospedaliero-Universitaria di Bologna, or all of them as a file.
02

Study summary

Scientific evidence established about the effects of night work on health both in the short term (insomnia, excessive sleepiness, difficulty concentrating or lack of energy) and in the long term (moderately high risk of developing cardiovascular disease, type 2 diabetes, depression, cancer). In light of the scientific evidence, the IARC (International Agency for Research on Cancer) has listed night work as a probable human carcinogen (Group 2). With respect to current knowledge, the present study could provide valuable help in understanding the mechanisms by which circadian rhythm alteration acts at the genetic level in terms of promoting oncogenesis. Furthermore, by studying its association with other risk factors, understand whether there is a pattern of women more susceptible to its oncopromoting action.

Read the detailed description

Certain bodily functions, such as wakefulness and sleep, regulation of blood pressure and body temperature, the immune system, gene expression, and secretion of hormones--think of cortisol, for example--follow variations that are stably repeated every 24 to 25 hours. The biological clock that marks this cyclical rhythm is represented by neurons in the suprachiasmatic nucleus of the hypothalamus. Of the circadian system, three components should be considered: (a) the input pathways that transmit signals to synchronize the endogenous central clock with the external environment, (b) the central clock generates rhythms, and (c) the output pathways that transmit the signal from the central clock to other regulatory systems in the brain and body. The most powerful regulator of the input pathways is light, which-as is well known-is captured by the five retinal photoreceptors, including the intrinsically photosensitive retinal ganglion cells [ipRGCs], which, through the production of melanopsin, transmit the signal to the central circadian clock. Such physiological mechanisms, which have remained unperturbed for thousands of years, have been disrupted by the spread of artificial lighting, which, inevitably, alters the natural synchronization of the internal clock with sunlight.

The effects that this misalignment produces are clearly visible in night workers who frequently have to expose themselves to light at "atypical" hours. In this sense, in fact, according to current legislation (see Art. 1, Legislative Decree No. 66 of April 8, 2003, implementing Directives 93/104/EC and 2000/34/EC, concerning certain aspects of the organization of working time), a night worker is defined as anyone who works for a period of at least seven consecutive hours including the interval between midnight and 5 a.m. It follows with palpable evidence that there is an increased risk that, under night work conditions, the alteration of the sleep-wake rhythm may take on a chronic character. In this regard, scientific evidence about the effects of night work on short-term health is well established: such as insomnia, excessive sleepiness, difficulty in concentration or lack of energy. While there is also scientific evidence that some repercussions may also occur in the long term. This is, in that case, the moderately high risk of developing cardiovascular disease, type 2 diabetes, depression, and, not least, cancer. Indeed, in 2007, in light of scientific evidence, the IARC (International Agency for Research on Cancer) listed night work as a probable human carcinogen (Group 2). Breast cancer generally represents the second most frequent neoplastic disease in women. The incidence of new cases worldwide in 2017 was estimated to be 1.9 million, higher in industrialized countries. From a pathogenetic point of view, the association between night shift work and breast cancer is highly plausible.

03

Conditions studied

  • Breast Cancer Risk Factors

Browse trials for

Keywords

  • Breast cancer
04

Who can participate

Ages eligible
20 Years to 70 Years
Sexes eligible
Female
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Health care workers with an employment relationship at IRCCS AOUBO Policlinico di S. Orsola and AOU "G. Martino" of Messina undergoing health surveillance, aged between 20 and 70 years at the time of recruitment (from January 1, 2000 until December 31, 2021).

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Health workers with any type of contract and qualification (doctors, nurses, OSS) in service at IRCSS AOUBO and AOU "G. Martino" of Messina for at least six months between 1.1.2000 and 31.12.2021
  • Age between 20 and 70 years at the start of study follow-up (6 months after recruitment or 1.1.2000)
  • Female gender
  • For secondary objective 2 of the study only, women exposed to night work must have worked at least 6 night shifts per month in the past six months

Exclusion criteria

Exclusion Criteria:

  • Women found to be positive for BRCA1 and BRCA2 genetic mutation (BRCA1 and 2 mutations are searched for by geneticists in sick women for whom there is a consistent suspicion of mutation)
  • Women with prior history of breast cancer at the time of recruitment or within six months thereafter.
05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
6,000 participants (estimated)
Patient registry
No

Groups and cohorts

  • Subgroup 1

    For the analysis of possible risk factors for breast cancer (secondary objective 1), a nested case-control study will be conducted on a subpopulation of the health worker cohort: 100 cases will be selected from the health workers in the cohort who have been diagnosed with breast cancer; 3 healthy controls will be selected for each case (300 total) and will be matched to the cases based on center, age, and period of first employment

    Other: Questionnaire

  • Subgroup 2

    For the measurement of biomarkers of aging whose expression might be associated with night shifts (secondary objective 2), 200 health care workers who have been exposed to at least 6 night shifts per month in the past 6 months and 200 unexposed health care workers, plus 50 other health care workers in each group to prevent possible nonadherence to the study, will be randomly selected from the cohort of health care workers currently still in service.

    Diagnostic Test: Blood samples for biomarker measurement

Interventions

  • OtherQuestionnaire

    All cases and controls will be contacted by telephone or e-mail and invited to participate in the study. Female workers who decide to join the study will be asked to go to their company's occupational health clinic where they will undergo administration of a questionnaire to investigate possible known and unknown risk factors for breast cancer

  • Diagnostic testBlood samples for biomarker measurement

    Women who give consent to undergo this phase of the study will be called back to the center and will be asked to provide a blood sample

06

What researchers measure

Primary outcomes

  1. Estimate the relationship between exposure to night work and breast cancer incidence

    The primary objective of the study is to estimate the relationship between exposure to night work and incidence of breast cancer in a cohort of female health care workers who have been in service at IRCCS AOUBO Policlinico di S. Orsola and Azienda Ospedaliero- Universitaria "G. Martino" in Messina.

    Time frame: through study completion, an average of 1 year

Secondary outcomes

  1. Identify by case-control analysis which risk factors are associated with the development of breast cancer

    identify by case-control analysis which risk factors are associated with the development of breast cancer and evaluate their effect on the relationship between exposure to night work and breast cancer occurrence among female health workers in the selected cohort

    Time frame: Six months from the start of follow-up

  2. Determine whether epigenetic alterations are more prevalent in the genome of women exposed to night work

    Determine whether epigenetic alterations attributable to the effect of altered sleep-wake rhythm are more present in the genome of women exposed to night work than in women not exposed to night work.

    Time frame: At enrollment in the study

07

Study locations

2 of 2 sites recruiting
  • IRCCS Azienda Ospedaliero - Universitaria di Bologna, U.O. Medicina del Lavoro
    Bologna, 40138, Italy
    Recruiting
  • AOU G. Martino Messina U.O.S.D. Medicina del Lavoro
    Messina, 98125, Italy
    Recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Jan 2025; primary completion for Jun 2025, 4 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 2, 2025
First posted
Jan 22, 2025
StartEst.
Jan 31, 2025
Primary completionEst.
Jun 30, 2025
CompletionEst.
Dec 31, 2025
Last update
Jan 22, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 22, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06786949
Responsible party
Sponsor
First posted
Jan 22, 2025
Start date
Jan 31, 2025 (estimated)
Primary completion
Jun 30, 2025 (estimated)
Completion
Dec 31, 2025 (estimated)
Last update
Jan 22, 2025

Study contacts

Francesco Violante Violante, MD
Contact
francesco.violante@asop.bo.it
051 2142611
Francesco Violante, MD
principal investigator · IRCCS Azienda Ospedaliero-Universitaria di Bologna

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion